Corporate Profile
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA®, is an FDA-approved corticosteroid indicated for the treatment of ocular inflammation and pain following ophthalmic surgery and the treatment of ocular itching associated with allergic conjunctivitis...
Data Provided by Refinitiv. Minimum 15 minutes delayed.